Why GLP-1 Receptor Agonists Are Becoming Essential Cardiovascular Drugs

Why GLP-1 Receptor Agonists Are Becoming Essential Cardiovascular Drugs

Introduction

GLP-1 Receptor Activation and Cardiovascular Tissue Expression

The distribution of GLP-1 receptors (GLP-1R) throughout cardiovascular tissues provides the anatomical foundation for the cardioprotective effects of GLP-1 receptor agonists. Understanding both receptor expression patterns and subsequent signaling cascades illuminates how these agents exert their beneficial cardiovascular actions beyond glycemic control.

GLP-1R expression in cardiomyocytes and vascular endothelium

GLP-1R expression extends well beyond pancreatic islets, with detectable presence throughout the cardiovascular system. Multiple studies have confirmed GLP-1R expression in all four chambers of the human heart, with transcript levels comparable to those observed in the pancreas [1]. However, the precise cellular localization within cardiac tissue has sparked scientific debate.

Research examining human cardiac samples has revealed several key findings:

• GLP-1R mRNA transcripts have been consistently detected in all four cardiac chambers from human hearts, at levels approximating those in human pancreas [1]
• Receptor expression is notably absent in cardiac fibroblasts, coronary artery endothelial cells, and vascular smooth muscle cells according to some studies [1]
• Human GLP-1R expression appears predominantly in cardiomyocytes, albeit at relatively low levels [2]

Interestingly, species differences exist in GLP-1R distribution patterns. While human GLP-1R expression occurs primarily in cardiomyocytes, murine cardiac Glp1r expression remains confined to endocardial cells [2]. This distinction highlights the importance of human-specific studies when evaluating cardiovascular effects.

Moreover, disease states appear to influence GLP-1R expression patterns. Human hearts with ischemic, dilated, and hypertrophic cardiomyopathy demonstrate upregulated GLP-1R expression in cardiomyocytes compared to non-failing hearts [2]. This upregulation during pathological states suggests a potential adaptive response that might enhance sensitivity to GLP-1 agonist therapy during heart failure.

The endothelial expression of GLP-1R has been more consistently documented. Vascular endothelial cells demonstrate functional GLP-1 receptors, providing a direct mechanism for the vasodilatory effects observed with GLP-1 agonists [3]. Additionally, studies have identified GLP-1R in vascular smooth muscle cells, though with more variable expression patterns [2].

GLP-1 agonist mechanism of action in cardiovascular tissues

Once activated, GLP-1 receptors trigger multiple signaling pathways that collectively contribute to cardioprotection. These pathways operate through several mechanisms:

The primary signaling cascade involves dual pathways: (1) Gαs-mediated activation of adenylyl cyclase leading to increased cAMP production and subsequent activation of protein kinase A (PKA) and exchange protein activated by cAMP (Epac), and (2) PI3K/Akt pathway activation [4]. These converging pathways ultimately enhance cardiomyocyte survival.

In vascular endothelium, GLP-1R stimulation activates both cAMP/PKA and PI3K/Akt signaling cascades, leading to phosphorylation of endothelial nitric oxide synthase (eNOS) and increased nitric oxide production [4]. This mechanism directly improves vasodilation and endothelial function.

At the cellular level, GLP-1 agonists exert several beneficial effects:

1. Cardiomyocyte protection: GLP-1 agonists inhibit receptor-interacting protein kinase 3/mixed lineage kinase domain-like pseudokinase-mediated myocardial necroptosis by activating the GLP-1R/PI3K/Akt pathway [5]
2. Anti-fibrotic effects: These agents alleviate cardiac fibrosis and hypertrophy by upregulating atrial natriuretic peptide expression, which suppresses the calcineurin/nuclear factor of activated T cells 3 signaling pathway [5]
3. Cellular stress reduction: GLP-1 agonists diminish endoplasmic reticulum stress and enhance autophagy in cardiomyocytes, preventing apoptosis and blocking progression to heart failure [5]
4. Vascular effects: In vascular smooth muscle cells, GLP-1R activation primarily leads to Gαs-mediated cAMP/PKA signaling while simultaneously inhibiting pro-proliferative pathways including ERK1/2 and p38 MAPK [4]

Beyond these direct cellular effects, GLP-1 agonists improve cardiac function through multiple systemic mechanisms. They enhance nitric oxide bioavailability, resulting in improved coronary blood flow and myocardial perfusion [4]. Furthermore, they promote myocardial glucose uptake and utilization while reducing oxidative stress [6].

The anti-inflammatory properties of GLP-1 agonists additionally contribute to their cardiovascular benefits. They reduce proinflammatory cytokines, including tumor necrosis factor-α and interleukin-6, thereby alleviating chronic systemic inflammation that contributes to heart failure progression [4].

Collectively, these mechanisms explain how GLP-1 receptor agonists exert their cardioprotective effects, with implications for managing cardiovascular risk across multiple patient populations.

Evidence from Cardiovascular Outcome Trials (CVOTs)

Multiple landmark clinical trials have firmly established the cardiovascular protective effects of GLP-1 receptor agonists (GLP-1 RAs), fundamentally altering treatment paradigms beyond diabetes management alone. These trials provide robust evidence for incorporating GLP-1 RAs into cardiovascular prevention strategies.

LEADER, SUSTAIN-6, and REWIND trial outcomes

The initial wave of cardiovascular outcome trials (CVOTs) predominantly focused on patients with type 2 diabetes at elevated cardiovascular risk. Among these, three pivotal studies demonstrated particularly noteworthy results:

The LEADER trial evaluated liraglutide (1.8 mg/day subcutaneous) in 9,340 patients, establishing a foundation for cardiovascular risk reduction with GLP-1 therapy [2]. Subsequently, SUSTAIN-6 examined semaglutide (0.5 mg/week or 1.0 mg/week subcutaneous) across 3,297 participants [2]. Both trials enrolled predominantly high-risk populations—81% of LEADER and 83% of SUSTAIN-6 participants had established cardiovascular disease [3].

REWIND expanded the evidence base by studying dulaglutide (1.5 mg/week subcutaneous) in a broader population that included a substantial proportion of primary prevention patients—only 31% of its 9,903 participants had established cardiovascular disease at baseline [3]. This distinction is particularly relevant for clinical practice, as REWIND demonstrated benefits in patients at moderate cardiovascular risk without previous events.

A comprehensive meta-analysis of eight GLP-1 RA CVOTs revealed several critical findings:

• 14% reduction in major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) [3]
• 13% reduction in cardiovascular death [3]
• 10% reduction in all-cause mortality [3]
• 11% reduction in hospitalization for heart failure [3]

Post-hoc analyzes from LEADER and SUSTAIN-6 revealed that cardiovascular benefits extended across the spectrum of body mass index categories, indicating efficacy regardless of baseline weight [2].

SELECT trial: GLP-1 RAs in non-diabetic patients

The SELECT trial represented a paradigm shift by evaluating semaglutide exclusively in patients without diabetes. This landmark study randomized 17,604 adults with overweight or obesity (BMI ≥27 kg/m²) and established cardiovascular disease to once-weekly subcutaneous semaglutide 2.4 mg versus placebo [1].

After a mean follow-up of 40 months, semaglutide demonstrated a 20% relative risk reduction in MACE compared to placebo (6.5% vs. 8.0%, HR 0.80, p<0.001) [1]. Absolute risk was reduced by 1.5%, yielding a number needed to treat of 67 to prevent one cardiovascular event [1].

Beyond MACE reduction, SELECT demonstrated several other benefits:

• 19% reduction in all-cause mortality (4.3% vs. 5.2%) [1]
• 18% reduction in first cardiovascular death or heart failure hospitalization (3.4% vs. 4.1%) [1]
• 28% reduction in nonfatal myocardial infarction (2.7% vs. 3.7%) [1]
• 22% reduction in nephropathy events (1.8% vs. 2.2%) [1]

Remarkably, these benefits occurred despite widespread use of guideline-directed preventive therapies, with 88% of participants receiving statins [1]. Furthermore, the cardiovascular benefits appeared early in the trial and extended to patients with heart failure, regardless of ejection fraction [1].

Table: Summary of GLP-1 RAs with proven cardiovascular benefit

*Did not reach statistical significance for superiority

As these results collectively demonstrate, GLP-1 RAs offer cardiovascular protection through mechanisms that extend beyond glycemic control, weight reduction, and traditional risk factor modification. Indeed, the emerging evidence positions these agents as essential tools in contemporary cardiovascular care.

GLP-1 Agonist Cardiovascular Benefit in Specific Conditions

Beyond their general cardiovascular protection, GLP-1 receptor agonists demonstrate targeted benefits in specific cardiac and renal conditions. Recent clinical trials have expanded our understanding of these agents’ therapeutic potential beyond the traditional type 2 diabetes population.

GLP-1 heart failure outcomes: STEP-HFpEF and SUMMIT trials

Heart failure trials reveal divergent outcomes depending on ejection fraction status. Initially, small studies examining liraglutide in heart failure with reduced ejection fraction (HFrEF) showed neutral or potentially concerning results. The LIVE study in 241 HFrEF patients reported no improvement in left ventricular ejection fraction, yet noted increased cardiovascular events in the liraglutide group [2]. Likewise, the FIGHT trial found no difference in primary endpoints after 180 days of liraglutide treatment [2].

In contrast, heart failure with preserved ejection fraction (HFpEF) shows more promising results:

• The STEP-HFpEF trial demonstrated that semaglutide produced substantial improvements in symptoms, physical limitations, and exercise function in patients with obesity and HFpEF [7]
• In the SUMMIT trial, tirzepatide reduced the combined endpoint of cardiovascular death or worsening heart failure events by 38% compared to placebo (HR 0.62) [4]
• Hospitalization for heart failure alone decreased by 56% with tirzepatide versus placebo (HR 0.44) [4]

These outcomes appear particularly robust in patients with obesity-related HFpEF. The SUMMIT trial also revealed a 6.9-point improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score with tirzepatide [4].

Meta-analyzes of CVOTs indicate an overall 11% reduction in hospitalization for heart failure with GLP-1 receptor agonists [2], suggesting class-wide benefits despite varying results in dedicated heart failure trials.

Renal protection and albuminuria reduction

Nephroprotective effects of GLP-1 receptor agonists manifest through several mechanisms. First and foremost, these agents consistently reduce albuminuria, a key marker of progressive kidney disease. In pooled analyzes, semaglutide/liraglutide decreased albuminuria from baseline by 24% versus placebo [5].

GLP-1 receptor agonists also slow eGFR decline:

• Semaglutide 1.0 mg slowed eGFR slope decline by 0.87 mL/min/1.73 m²/year [5]
• Liraglutide slowed eGFR decline by 0.26 mL/min/1.73 m²/year [5]
• Dulaglutide demonstrated slower eGFR decline compared to insulin glargine in patients with CKD stages 3-4 [2]

More impressively, these agents reduce hard renal outcomes. Semaglutide/liraglutide lowered the risk of persistent 40% and 50% eGFR reductions by 14% and 20%, respectively [5]. The effect appears particularly pronounced in patients with pre-existing kidney disease—those with baseline eGFR 30-60 mL/min/1.73 m² showed a 29% reduction in persistent 30% eGFR decline [5].

The FLOW trial examining semaglutide in diabetic nephropathy was halted early due to overwhelming efficacy [7], further supporting the renal protective effects of GLP-1 receptor agonists.

Stroke and myocardial infarction risk reduction

Individual components of the composite MACE outcome show consistent benefit. A comprehensive meta-analysis of eight cardiovascular outcome trials revealed:

• 10% reduction in myocardial infarction risk [2]
• 13% reduction in non-fatal stroke [8]
• 14% reduction in cardiovascular death [8]

The strongest effect appears to be on stroke prevention. In the REWIND trial, dulaglutide reduced stroke by 24% [2], while semaglutide demonstrated a 39% reduction in stroke events in the SUSTAIN-6 trial [6].

Recent head-to-head comparisons suggest differential effects among GLP-1 receptor agonists. In a real-world Medicare analysis, semaglutide was associated with a 23% lower risk of heart attack, stroke, and death compared to dulaglutide in patients with type 2 diabetes and atherosclerotic cardiovascular disease [9].

These findings establish GLP-1 receptor agonists as essential tools for cardiovascular protection across multiple high-risk conditions, with evidence increasingly supporting their use regardless of diabetes status.

Mechanisms Behind Cardiovascular Risk Reduction

Clinical Guidelines and Patient Selection Criteria

Professional societies have updated clinical guidelines to incorporate GLP-1 receptor agonists (GLP-1 RAs) as essential cardiovascular medications based on extensive trial evidence. These recommendations help clinicians determine optimal patient selection and medication choice.

Which GLP-1 is best for cardiovascular benefit?

Among FDA-approved medications, certain GLP-1 RAs demonstrate superior cardiovascular protection. Clinical trial and real-world data support:

• Semaglutide (subcutaneous) showing a 26% MACE reduction in SUSTAIN-6 [2]
• Liraglutide reducing cardiovascular death by 22% in the LEADER trial [17]
• Dulaglutide decreasing stroke risk by 24% in REWIND [17]

The SELECT trial established semaglutide 2.4 mg as particularly effective, reducing MACE by 20% in non-diabetic patients with obesity and established cardiovascular disease [18]. Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates slightly greater weight loss in both clinical trials and real-world data [19].

ADA and ESC recommendations for GLP-1 RA use

The European Society of Cardiology (ESC) provides strong endorsement for GLP-1 RAs with proven cardiovascular benefit (liraglutide, semaglutide, dulaglutide, efpeglenatide) in patients with T2DM and atherosclerotic cardiovascular disease (Class I, Level A) [18]. Correspondingly, the American Diabetes Association (ADA) recommends GLP-1 RAs with demonstrated cardiovascular benefit for patients with established ASCVD or at high risk, independent of baseline HbA1c, target HbA1c, or metformin use [3].

For non-diabetic patients, the 2025 American College of Cardiology (ACC) guidance states that semaglutide should be considered in overweight (BMI >27 kg/m²) or obese chronic coronary syndrome patients to reduce cardiovascular mortality, MI, or stroke (Class IIa, Level B) [18].

Patient profiles: ASCVD, obesity, and high HbA1c

Patient selection criteria for cardiovascular risk reduction with GLP-1 RAs include:

1. Established ASCVD: Defined as MI, stroke, revascularization, unstable angina, or symptomatic coronary artery disease [3]
2. High cardiovascular risk without ASCVD: Age >55 years with two additional risk factors (obesity, hypertension, smoking, dyslipidemia, albuminuria) [3]
3. Obesity with cardiovascular disease: BMI ≥27 kg/m² with existing cardiovascular disease even without diabetes [18]
4. Heart failure focus: Patients with HFpEF appear to benefit more than those with HFrEF [20]

Yet despite their proven benefits, accessibility remains challenging. Currently, most insurance coverage for GLP-1 RAs is limited to patients with type 2 diabetes, although their use for cardiovascular risk reduction in non-diabetic patients continues to gain support from clinical evidence [21].

Practical Use, Safety, and Drug Administration

Practical implementation of GLP-1 receptor agonist therapy requires careful consideration of administration routes, side effect management, and safety constraints for optimal cardiovascular benefit delivery.

Oral vs injectable GLP-1 RAs: dosing and adherence

Administration options for GLP-1 receptor agonists include daily oral tablets (semaglutide), daily injections (liraglutide, lixisenatide), and weekly injections (semaglutide, dulaglutide, exenatide-ER). One-year adherence data reveals oral semaglutide achieves the highest mean proportion of days covered (82.4%) versus injectable formulations [22]. At this timepoint, 65.1% of oral semaglutide users maintained high adherence compared to 59.1% with dulaglutide [23]. Nevertheless, oral semaglutide requires administration 30 minutes before food or beverages with only 4 ounces of water [24].

Managing GI side effects and titration strategies

Gastrointestinal adverse events affect 40-70% of treated patients [25], primarily consisting of:

• Nausea (15-50%)
• Diarrhea (5-25%)
• Vomiting (5-10%)

Slow titration remains fundamental to mitigating these effects. For subcutaneous semaglutide, begin with 0.25 mg weekly for 4 weeks, increase to 0.5 mg weekly, then to 1.0 mg after another 4 weeks if needed [4]. For oral semaglutide, start with 3 mg daily for 1 month, increase to 7 mg, then 14 mg after another month if necessary [4].

Practical strategies for managing GI symptoms include smaller meal sizes, avoiding high-fat foods, and stopping eating when full [4]. If symptoms persist, temporarily pausing dose escalation or returning to a lower dose may be warranted [25].

Contraindications: pancreatitis, thyroid cancer, gastroparesis

Absolute contraindications include hypersensitivity to the drug, history of medullary thyroid carcinoma, and multiple endocrine neoplasia syndrome type 2 [24]. GLP-1 RAs should be avoided in patients with severe gastroparesis or inflammatory bowel disorders [24]. Temporary discontinuation is recommended one week before surgery [26].

Current evidence does not support significantly increased pancreatitis risk in randomized controlled trials [7]. Mild increases in amylase and lipase often remain within normal ranges without progression to acute pancreatitis [7]. For patients with severe renal impairment, dose adjustment or alternative agent selection may be necessary [24].

Conclusion   

GLP-1 receptor agonists have emerged as essential tools in cardiovascular medicine, transcending their original purpose as antihyperglycemic agents. Robust evidence from multiple landmark trials demonstrates their consistent ability to reduce major adverse cardiovascular events by 14%, with notable benefits extending beyond glycemic control. Therefore, these medications deserve consideration as primary cardiovascular drugs rather than merely adjunctive diabetes therapies.

The cardiovascular protection offered by GLP-1 receptor agonists stems from several complementary mechanisms:

• Anti-inflammatory effects through suppression of CRP, TNF-α, and other inflammatory markers • Substantial weight reduction, particularly with higher doses of newer agents • Blood pressure modulation via direct vascular effects and enhanced natriuresis • Improved endothelial function and lipid profiles • Renal protective effects, including reduced albuminuria and slowed eGFR decline

Though initially established in type 2 diabetes populations, recent evidence from the SELECT trial confirms these benefits extend to non-diabetic patients with obesity and established cardiovascular disease. Furthermore, specific patient subgroups appear to derive particular advantages, including those with heart failure with preserved ejection fraction, chronic kidney disease, and high stroke risk.

Clinicians must nevertheless balance these impressive cardiovascular benefits against practical considerations. Gastrointestinal side effects remain common, titration strategies require patience, and certain patients—especially those with medullary thyroid carcinoma, severe gastroparesis, or history of pancreatitis—may not qualify for therapy. Additionally, insurance coverage continues to lag behind clinical evidence, particularly for cardiovascular indications in non-diabetic patients.

Current guidelines from the European Society of Cardiology and American Diabetes Association strongly endorse GLP-1 receptor agonists with proven cardiovascular benefit for patients with established atherosclerotic cardiovascular disease. Yet prescribing patterns indicate these recommendations have not yet fully penetrated clinical practice.

As mounting evidence confirms their role in reducing cardiovascular morbidity and mortality, GLP-1 receptor agonists will undoubtedly become standard components of cardiovascular risk reduction strategies. While initially viewed as diabetes medications with cardiovascular side benefits, these agents now warrant recognition as fundamental tools in the cardiologist’s armamentarium—truly essential cardiovascular drugs for the modern era.

Key Takeaways

GLP-1 receptor agonists have evolved from diabetes medications into essential cardiovascular drugs, offering proven protection against heart attacks, strokes, and cardiovascular death across diverse patient populations.

• GLP-1 RAs reduce major cardiovascular events by 14% through multiple mechanisms beyond glucose control, including anti-inflammatory effects and blood pressure reduction
• SELECT trial proved cardiovascular benefits extend to non-diabetic patients with obesity, showing 20% MACE reduction in those without diabetes
• Semaglutide, liraglutide, and dulaglutide demonstrate the strongest cardiovascular protection, with proven benefits in large outcome trials
• These agents provide specific benefits for heart failure with preserved ejection fraction and kidney protection, reducing albuminuria by 24%
• Current guidelines strongly recommend GLP-1 RAs for patients with established cardiovascular disease, regardless of diabetes status or HbA1c levels

The evidence positions GLP-1 receptor agonists as fundamental cardiovascular medications rather than merely diabetes drugs with heart benefits. Their multi-pathway approach to cardiovascular protection—combining weight loss, inflammation reduction, and direct vascular effects—makes them essential tools for modern cardiovascular risk management, though practical considerations like GI side effects and insurance coverage remain important implementation challenges.

Frequently Asked Questions:   

FAQs

Q1. How do GLP-1 receptor agonists improve cardiovascular health? GLP-1 receptor agonists improve cardiovascular health through multiple mechanisms. They reduce inflammation by suppressing markers like CRP and TNF-α, promote weight loss, lower blood pressure, improve lipid profiles, and enhance endothelial function. These agents also have direct protective effects on the heart and blood vessels, contributing to a 14% reduction in major adverse cardiovascular events.

Q2. What are the cardiovascular benefits of semaglutide? Semaglutide has shown significant cardiovascular benefits in clinical trials. It reduces major adverse cardiovascular events (MACE) by 20-26% in patients with and without diabetes. In heart failure patients with preserved ejection fraction, semaglutide improves exercise capacity and NT-proBNP levels. It also lowers inflammatory markers like CRP and TNF-α, which may contribute to reduced atherosclerotic risk.

Q3. Can GLP-1 receptor agonists benefit patients without diabetes? Yes, GLP-1 receptor agonists can benefit patients without diabetes. The SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in non-diabetic patients with obesity and established cardiovascular disease. These medications are now being considered for cardiovascular risk reduction in overweight or obese patients with heart disease, regardless of diabetes status.

Q4. How do GLP-1 receptor agonists affect heart rate and blood pressure? GLP-1 receptor agonists generally lower blood pressure by 2-6 mm Hg through multiple mechanisms, including weight loss, improved endothelial function, and enhanced natriuresis. While acute administration may temporarily increase heart rate in some studies, long-term use typically results in sustained blood pressure reduction. The overall effect contributes to their cardiovascular protective benefits.

Q5. What are the main side effects and contraindications of GLP-1 receptor agonists? The most common side effects of GLP-1 receptor agonists are gastrointestinal, including nausea, diarrhea, and vomiting, affecting 40-70% of patients. These can often be managed with slow dose titration and dietary adjustments. Main contraindications include a history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastroparesis. Caution is advised in patients with a history of pancreatitis or severe renal impairment.

References:  

[Internal Medicine -Home]

Video Section

Check out our extensive video library (see channel for our latest videos)

Recent Articles

• Micro-Behaviors and Macro-Mindsets: An Analysis of Subtle Human Reactions
• Burnout vs. Breakthrough: Why Some Doctors Find Joy Again After Leaving Clinical Practice
• The Truth About Physician Financial Myths: What Most Doctors Get Wrong
• Revisiting Lyme Disease Management in Primary Care
• The Psychology of Everyday Life: How Small Behaviors Reflect Deep Cognitive and Emotional Processes
• Managing ADHD in Adults: A Growing Primary Care Responsibility
• Raw Honey and Early Morning Awakening: Clinical Considerations
• Hemophilia Prophylaxis in the Era of Non-Factor Therapies
• Hidden Cognitive Decline Symptoms: What Every Internist Must Know Today
• Alternative Therapies for Depression: Breakthrough Neurostimulation Methods Show 80% Success Rate
• Pediatric Sepsis: Can Rapid Genomic Diagnostics Save Lives?
• Psychedelics for Acute Suicidality: Could the ED Become the Frontline?
• Pulse Pressure Variation: The Missing Key to Fluid Responsiveness in ED
• Screen Time, Social Media, and Teen Mental Health: What Can Family Physicians Do?
• Should Family Physicians Routinely Screen for Depression and Anxiety?
• Why Standard Blood Pressure Targets After Surgery May Be Harming Your Patients
• Evidence-Based Insights into Everyday Human Behavior
• Fascinating Psychological Insights- Evidence-Based Observations About How the Human Mind and Behavior
• Glycine’s Role in Sleep Enhancement- Clinical Evidence, Mechanisms, and Therapeutic Applications
• Early Morning Awakening Syndrome- Understanding Cortisol Dysregulation
• Why GLP-1 Non-Responders Need Earlier Anti-Obesity Medication Intervention
• Tachyphylaxis in Antidepressants: The Science Behind Treatment Resistance
• The Opioid Crisis in Family Practice: Safe Prescribing vs. Abandoning Patients
• 70 Psychology Facts That Explain How the Mind and Behavior Interact
• 100 Timeless Lessons for Growth, Success, and Happiness — With Healthcare Applications
• The Hidden Patterns of the Human Mind Evidence-Based Insights
• Asthma vs. COPD in Primary Care: Are We Missing Asthma-COPD Overlap?
• Lung Cancer Screening in Primary Care: Why Uptake Remains Low
• The Hidden Cost of Skipping Frailty Assessment: New Research Reveals
• The Spectrum of AI Influence- Comparative Impact Across Medical Specialties